Abraham Noah Oler
President at Allos Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Rajesh Shrotriya | M | 79 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 24 years |
| Luigi Lenaz | M | 83 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 years |
| Bimal Shah | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 years |
| Keith M. McGahan | M | - | 8 years | |
| William Pelham Barr | M | 73 |
Kirkland & Ellis LLP
 Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 15 years |
| Jeffrey R. Latts | M | 76 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 17 years |
| Mary Shoemaker | F | 63 | 4 years | |
| Rick Shrotri | M | - |
Digital Alpha Advisors LLC
 Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 7 years |
| James E. Shields | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 years |
| Harry Kraemer | M | 69 |
Kellogg School of Management
| 19 years |
| Jesus R Vega | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 3 years |
| Matthew Parris | M | - | 6 years | |
| Shiju Rajagopalan | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 2 years |
| Terry Whalen | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 3 years |
| Karl Meyer | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 3 years |
| Jeff Frazier | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 5 years |
| Olsen Edward | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 4 years |
| Dave Ward | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 4 years |
| Scott Puopolo | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 3 years |
| Andy Alcon | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | - |
| Michael A. Grabow | M | - | 11 years | |
| David L. Dixon | M | - |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 17 years |
| Bradley C. Reed | M | - |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 17 years |
| Cornelius Sheridan | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 4 years |
| Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 years |
| Vasa Babic | M | 57 |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 5 years |
| Daniel E. Wolf | M | - |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 15 years |
| Davis Stowell | M | 71 |
Kellogg School of Management
| 19 years |
| Rachel Masory | F | - |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 15 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Riga | M | 48 | 10 years | |
| Joseph W. Turgeon | M | 66 | 9 years | |
| Ramesh Kumar | M | 68 | 21 years | |
| Michael Hoffman | M | 73 | 18 years | |
| Kurt Gustafson | M | 56 | 9 years | |
| Brett Scott | M | 73 | - | |
| Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 years |
| Jeffrey C. Hammes | M | 64 |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | - |
| Joseph C. Dwyer | M | - |
Northwestern University School of Law
| 3 years |
| Wing Kun Hui | M | 43 |
London School of Economics & Political Science
| 5 years |
| Raul Ramirez | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Peter M. Lamb | M | - |
University of Pennsylvania
| 3 years |
| R. Kenneth Bryant | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Erik Oliver | M | - |
University of Pennsylvania
| 3 years |
| Irene Rika Shimada | F | - |
London School of Economics & Political Science
| 4 years |
| Elizabeth Stevens | F | 45 |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Saul Goldstein | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Nazar Yasin | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Ben Gulliver | M | - |
London School of Economics & Political Science
| 4 years |
| Paras P. Maniar | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Zain Al-Abidin ibni Muhriz | M | 41 |
London School of Economics & Political Science
| 5 years |
| Ee Ern Tan | M | 44 |
London School of Economics & Political Science
| 5 years |
| Nicholas Ng | M | - |
London School of Economics & Political Science
| 4 years |
| Shaia D. Hosseinzadeh | M | - |
London School of Economics & Political Science
| 4 years |
| Aydin Senkut | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Iskandar Saleh | M | 68 |
University of Pennsylvania
| 1 years |
| Mei Qing Ren | F | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Gabe Greenbaum | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Robert Fralin | M | - | - | |
| Nathalie Tocci | M | 47 |
London School of Economics & Political Science
| 5 years |
| Dolatrai Vyas | M | 80 | 9 years | |
| Krishan K. Arora | M | 83 | 3 years | |
| Leon Kuan | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| J. Kim | M | 55 |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 4 years |
| James S. Riepe | M | - |
University of Pennsylvania
| 4 years |
| Anton G. Gueth | M | 67 | 1 years | |
| David Clark | M | 56 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 years |
| Marc H. Graboyes | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 years |
| Leonard M. Greenstein | M | 48 | 7 years | |
| Ricardo J. Gonzalez | M | 53 | 6 years | |
| Jonathan Leff | M | 55 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 7 years |
| David Stout | M | 69 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 years |
| Raymond Cohen | M | 65 | 7 years | |
| Richard Thompson | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| David M. Hollond | M | - |
University of Pennsylvania
| 2 years |
| Bernice Welles | M | 71 | - | |
| Gilles Gagnon | M | 70 | - | |
| Sebastian Arango | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Alex Lloyd | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Atif U. Gilani | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 4 years |
| Joel Lloyd Gantcher | M | - |
University of Pennsylvania
| 2 years |
| E. Premkumar Reddy | M | 80 | 22 years | |
| Phil Bronner | M | 53 |
The Wharton School of the University of Pennsylvania
| 3 years |
| Maja M. Gross | F | - |
The Wharton School of the University of Pennsylvania
| 6 years |
| Fernando Goni | M | 50 |
London School of Economics & Political Science
| 5 years |
| Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
| Sandeep Murthy | M | 47 |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 4 years |
| Steve Carlson | M | - |
Kellogg School of Management
The Wharton School of the University of Pennsylvania
| 6 years |
| Erik Mayo | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 4 years |
| George Ng | M | 49 | 3 years | |
| Stuart Michael Frenkiel | M | 44 |
Kellogg School of Management
| 2 years |
| Sara Otepka | F | - |
Kellogg School of Management
| 2 years |
| Peter Koldgaard Eriksen | M | - |
Kellogg School of Management
| 2 years |
| Yannick Jean-Francois Archambault | M | - |
Kellogg School of Management
| 1 years |
| Mariano González | M | - |
Kellogg School of Management
| - |
| Scott Phillips | M | - |
Kellogg School of Management
| 4 years |
| David Klein | M | - |
Kellogg School of Management
| 2 years |
| Qi Chen | F | 47 |
Kellogg School of Management
| 2 years |
| Ankur Manglik | M | 48 |
Kellogg School of Management
| 2 years |
| Shanok Nate | M | - |
Kellogg School of Management
| 2 years |
| Brian Michael Price | M | - |
Kellogg School of Management
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 91 | 91.00% |
| United Kingdom | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Abraham Noah Oler
- Personal Network
